Prevention of healthcare-associated Clostridium difficile infection: What works?

Erik R. Dubberke
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/810

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Prevention of Healthcare-Associated *Clostridium difficile* Infection: What Works?

Erik R. Dubberke, MD, MSPH

Prevention of *Clostridium difficile* infection has become extremely important because of increases in its incidence and severity. Unfortunately, efforts at *C. difficile* infection prevention are hampered by lack of data to support optimal prevention methods, especially for endemic *C. difficile* infection. Studies are needed to define the optimal prevention practices and to investigate novel prevention methods.

**WHAT WORKS**

The Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals\(^2\) grades all recommended practices to prevent healthcare-associated infections on the basis of the strength of the recommendation and the quality of evidence to support that recommendation (recommendations require a minimum strength of “B” to be included). There are 16 recommended practices in the *C. difficile* component of the Compendium.\(^1\) Twelve of the practices have a grade of “B-III,” or moderate strength of evidence to support the recommendation and evidence from opinions of respected authorities, clinical experience, or descriptive studies. Two practices have a grade of “B-II,” or moderate strength of evidence to support the recommendation and evidence from nonrandomized trials, cohort or case-control studies, multiple time series, or dramatic results of uncontrolled experiments. There are only 2 practices with a strength of “A,” or good evidence to support the recommendation. One has a grade of “A-II.” The other is the only recommended practice to prevent CDI that has evidence from a randomized trial and therefore has a grade of “A-I.”

The single recommended practice to prevent CDI that is graded “A-I” is to wear gloves when caring for a patient with CDI. A study conducted prior to the advent of universal and standard precautions randomized 4 wards with similar baseline rates of CDI to provide standard of care or to conduct an educational intervention.\(^3\) The intervention consisted of an educational campaign instructing nurses to wear gloves.
when handling body fluids, especially stool. Boxes of gloves were placed at each patient’s bedside on the intervention wards. There was a statistically significant decrease in CDI incidence on the intervention wards, from 7.7 to 1.5 cases per 1,000 patient-days ($P = .029$), but no significant difference on the control wards (from 17% to 9% of patients; $P = .001$). No data were collected on compliance with components of the bundle before or after the intervention, so it is unclear which component of the bundle may have had the greatest impact. However, there was a significant increase in the number of stool specimens sent to the laboratory for $C. difficile$ testing after the intervention, despite the decrease in the number of patients who received a diagnosis of CDI, suggesting that more-rapid case finding and initiation of CDI prevention practices that occur after a patient receives a diagnosis of CDI contributed to a decrease in CDI incidence.

**How Low Is Low Enough?**

As previously stated, most data on CDI prevention come from outbreaks. When studied, many of the recommended practices to prevent CDI during outbreaks appear less effective in settings of endemicity. The lack of knowledge on how to further decrease CDI incidence in settings of endemicity is stressed in the current draft of the “Action Plan to Prevent Healthcare-Associated Infections” by the US Department of Health and Human Services; it states that the “preventability of endemic CDI is unknown.” Therefore, we must consider whether new approaches to CDI prevention are needed. Two areas that need to be investigated further are whether there are unrecognized sources of $C. difficile$ transmission or whether there are additional methods that can prevent CDI before the onset of symptoms.

There may be unrecognized sources of $C. difficile$ transmission in the hospital and community. Several recent publications have found $C. difficile$ contamination of food. $C. difficile$ can also contaminate hospital linens. Contaminated linens can then serve as a vector to contaminate other linens during the laundering process. Although past studies have found that the major source of $C. difficile$ transmission is from patients with symptomatic CDI, $C. difficile$ can be transmitted from asymptomatic carriers. Unfortunately, there are no validated methods to detect asymptomatic $C. difficile$ carriers, and existing data indicate that currently available methods are not sufficiently sensitive or specific for the rapid detection of asymptomatic $C. difficile$ carriers. Unrecognized sources of $C. difficile$ transmission and methods to prevent transmission from these sources need to be investigated.

Most efforts to prevent CDI occur after a patient develops symptomatic infection. Prevention of CDI in settings of endemicity may require emphasis on early prevention efforts—that is, before the onset of CDI. One method being investigated is to identify patients at high risk for CDI through a risk prediction model. Interventions could then be designed
to decrease the risk in patients identified as high risk for CDI. Another approach being investigated is the administration of nontoxigenic C. difficile to protect against colonization by toxigenic C. difficile, thus preventing CDI. In animal models, administration of nontoxigenic C. difficile prior to challenge with toxigenic C. difficile has been shown to be effective at prevention of both an initial episode of CDI and recurrence of CDI. A third area that holds promise is immunotherapy. Patients asymptptomatically colonized with C. difficile have higher titers of antibodies against C. difficile, patients who develop an anamnestic antibody after C. difficile acquisition are at lower risk to develop CDI, and patients who fail to produce antibodies against C. difficile after an episode of CDI are at increased risk for developing recurrent episodes. A recently published phase II trial evaluating anti–C. difficile toxin monoclonal antibodies as adjunctive treatment for CDI in addition to standard-of-care antibiotic treatment (with metronidazole or vancomycin) demonstrated that patients who received the monoclonal antibodies were significantly less likely to have a recurrent episode of CDI, compared with patients who received placebo (7% vs 25%; P < .001). It is unlikely that a biological agent, such as monoclonal antibodies, will be used as primary prophylaxis, because of the typically high cost of such products. However, the results of the trial suggest that CDI may at some point be added to the list of vaccine-preventable diseases.

CONCLUSION

Currently, CDI prevention efforts are hampered by a lack of high quality data to support most recommended prevention practices, with only 2 practices that have good evidence to support them (wearing gloves and antimicrobial stewardship). This makes the role of infection prevention and control even more important when designing a CDI prevention program or CDI bundles of CDI-related prevention practices, as infection prevention and control must determine which prevention practices to apply on the basis of local patient care practices and CDI epidemiology. Currently, recommended practices appear to be most effective when instituted in response to a CDI outbreak, and the best methods to prevent CDI in settings of endemicity are not known. More research is needed to identify all sources of C. difficile transmission and novel CDI prevention practices in order to significantly decrease rates of CDI in hospitals across the United States.

ACKNOWLEDGMENTS

I acknowledge and thank Kimberly A. Reske and Victoria J. Fraser, for editorial assistance.

Potential conflicts of interest. E.R.D. reports that he has served as a consultant to Merck, Meridian, and Becton-Dickinson and has received research funding from ViroPharma and Merck.

Supplement sponsorship. This article is part of an ICHE supplement entitled ”Papers from the Fifth Decennial International Conference on Healthcare-Associated Infections,” sponsored by the 5th Decennial on Healthcare-Associated Infections, LLC. The supplement contains selected papers from the conference, which was held in Atlanta, Georgia, on March 18–22, 2010, and was co-organized by the Society for Healthcare Epidemiology of America, the Centers for Disease Control and Prevention, the Association for Professionals in Infection Control, and the Infectious Diseases Society of America.

Address reprint requests to Erik R. Dubberke, MD, MSPH, 660 S Euclid Avenue, PO Box 8051, St. Louis, MO 63110 (edubberke@dom.wustl.edu).

REFERENCES

17. Carbone HL, Hellickson LA, Thomasser AI, Vu LK. Clostridium difficile cross contamination in the textile laundering process: the importance of
selecting an appropriate hard surface disinfectant. In: Program and abstracts of the 5th Decennial International Conference on Healthcare-Associated Infections; March 18–22, 2010; Atlanta, GA. Abstract 160.


